Bio-Path Holdings Email Formats

Biotechnology Research • Bellaire, Texas, United States • 1-10 Employees

Bio-Path Holdings Email Formats

Bio-Path Holdings uses 1 email format. The most common is {first initial}{last name} (e.g., jdoe@biopathholdings.com), used 100% of the time.

Format	Example	Percentage
{first initial}{last name}	jdoe@biopathholdings.com	100%

Key Contact at Bio-Path Holdings

Anthony Price

Senior Vice President - Finance, Accounting & Administration

Company overview

Headquarters	4710 Bellaire Blvd, Suite 210, Bellaire, Texas 77401, US
Phone number	+18327421357
Website	biopathholdings.com
NAICS	541714
Employees	1-10
Socials

About Bio-Path Holdings

Bio-Path is a biotechnology company developing targeted therapies for acute myeloid leukemia (AML), lymphoma, chronic lymphocytic leukemia, gynecological cancer and other challenging cancers. The company’s lead product candidate, prexigebersen (Liposomal Grb2 Antisense), formerly BP1001, is currently being assessed in a Phase 2 clinical study in previously untreated AML patients, who are not eligible for or who have decided to forego intensive chemotherapy because of their fragile health, and in refractory/relapsed AML patients. Additionally, BP1001-A is being assessed in a Phase 1 study in refractory/relapsed patients with solid tumors. The Company’s second product BP1002 (Liposomal Bcl-2 Antisense) is being evaluated in Phase 1 trials in patients with refractory/relapsed lymphoma and AML.